Robert J. Motzer, MD, discusses the importance of risk stratification in advanced renal cell carcinoma, and describes the MSKCC and international models that assist with prognosis, and for use in clinical trials.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
Ещё видео!